ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative, non-surgical therapies for urothelial and specialty cancers, today announced new post-hoc analyses from the Phase 3 ENVISION trial showing that ZUSDURI™ (mitomycin) for in ...